Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest OrbusNeich Stories

2014-04-02 16:31:50

DUBLIN, April 2, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/znsx2b/global_and ) has announced the addition of the "Global and Chinese Coronary Stent Industry Report 2014" [http://www.researchandmarkets.com/research/znsx2b/global_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Global and Chinese Coronary Stent Industry Report 2014 is a professional and in-depth study on...

2014-03-28 08:27:19

Post-Market Registry to Evaluate Long-Term Safety and Performance in Routine Practice HONG KONG, March 28, 2014 /PRNewswire/ -- OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the COMBO Stent for the treatment of coronary...

2014-03-25 16:25:35

DUBLIN, Mar. 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/k8gx4n/china ) has announced the addition of the "Concise Analysis of the International Interventional Cardiovascular Device Industry" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning...

2014-02-26 04:21:30

Company Initiates Joint U.S. and Japanese Registration Trial HONG KONG, Feb. 26, 2014 /PRNewswire/ -- OrbusNeich today announced that patient enrollment has been initiated in Japan in the pivotal clinical trial of the COMBO Dual Therapy Stent(TM) (COMBO Stent) employing a single Japan-U.S. protocol conducted as a Global Clinical Trial "proof-of-concept" under the framework of the joint Japan-U.S. Harmonization-By-Doing [HBD] initiative. The first patient was enrolled at Shonan...

2014-02-13 12:27:49

LONDON, Feb. 13, 2014 PRNewswire/ -- Reportbuyer.com just published a new market research report:China Interventional Cardiovascular Device Industry Report, 2013-2015 With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients...

2014-01-20 12:25:09

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Medical Devices Industry and Market Prospects 2013-2023 Report Details Medical devices - your guide to developments, opportunities, and revenuesWhat does the future hold for medical devices? Visiongain's report shows you potential revenues to 2023, assessing data, trends, opportunities and prospects in this market. Our study gives you revenue forecasts to 2023 at overall world market...

2013-11-14 12:27:34

DUBLIN, November 14, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/p5z6bs/2012_deep) has announced the addition of the "2012 Deep Research Report on Global and China Coronary Stent Industry" [http://www.researchandmarkets.com/research/p5z6bs/2012_deep ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This 2012 Deep Research Report on Global and China Coronary Stent Industry is a...

2013-10-29 20:22:40

Data from the EGO-COMBO Study Presented at TCT 2013 SAN FRANCISCO, Oct. 29, 2013 /PRNewswire/ -- OrbusNeich today announced that new clinical data presented at TCT 2013 show durable outcomes as well as excellent early healing and optimal neointimal suppression out to 24 months following placement of the COMBO Dual Therapy Stent. These results from the EGO-COMBO Study were presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China, at the annual...

2013-10-22 12:28:16

Company's Scoreflex(TM) Coronary Dilatation Catheter and Pro-Healing Drug Eluting Bioresorbable Scaffold Will Also Be Featured HONG KONG, Oct. 22, 2013 /PRNewswire/ -- OrbusNeich today announced that clinical data for the COMBO Dual Therapy Stent will be presented at Transcatheter Cardiovascular Therapeutics (TCT) 2013, Oct. 27-Nov. 1, in San Francisco. The scientific sessions will feature results from the EGO-COMBO Study assessing the healing profile of COMBO by optical coherence tomography...

2013-10-01 08:31:13

-- Hefei Life Science will fund and manage clinical development and distribution -- DURHAM, N.C., Oct. 1, 2013 /PRNewswire/ -- Micell Technologies, Inc. has entered into an agreement with Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life Science), for the clinical development, marketing and distribution of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(®))( )in the People's Republic of China ("PRC"), including...